Related Experiment Video
Updated: Jun 9, 2026

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
Case Series Assessing the Use of Levetiracetam for Gait Improvement in Primary Lateral Sclerosis
Matti Douglas Allen1,2,3, Danielle Carter4, Jodi Warman-Chardon3,5
1Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
Abstract:
In this retrospective case series, we present two patients with primary lateral sclerosis (PLS) and spasticity-related gait impairment. Both patients were assessed with 6-min walk tests (6MWT) and timed up and go (TUG) at baseline and after 4 weeks of oral levetiracetam. Following levetiracetam therapy, Patient 1 improved 27.3% (148.5 to 189 m) on 6MWT and 26.1% (23-17 s) on TUG. Patient 2 improved 18% (90 m in 4:29 min to 112 m in 6 min) on 6MWT and 10% (46-41 s) on TUG. Larger prospective trials of levetiracetam for spasticity and gait may be considered in PLS.

